Aligos therapeutics announces ind clearance for nash lead, alg-055009

- phase 2a nash protocol on track to be submitted to the ind in q4 2023, enrollment expected to begin in q1 2024 - phase 2a nash protocol on track to be submitted to the ind in q4 2023, enrollment expected to begin in q1 2024
ALGS Ratings Summary
ALGS Quant Ranking